The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis
Open accessAbstract
Osteoporotic fractures are a major cause of morbidity in the elderly population. Since postmenopausal osteoporosis is related to an increase in osteoclastic activity at the time of menopause, inhibitors of bone resorption have genuinely been considered an adequate strategy for prevention and treatment of osteoporosis. Bisphosphonates and selective oestrogen receptor modulators are widely prescribed to treat osteoporosis. However, other antiresorptive drugs have been developed for the management of osteoporosis, with the objective of providing a substantial reduction in osteoporotic fractures at all skeletal sites, combined with an acceptable long-term skeletal and systemic safety profile. Denosumab, a human monoclonal antibody to receptor activator for nuclear factor kappa B ligand, has shown efficacy against vertebral, nonvertebral and hip fractures. Its administration every 6 months as a subcutaneous formulation might significantly influence compliance and persistence to therapy. Additional results regarding long-term skeletal safety (i.e. osteonecrosis of the jaw and atypical diaphyseal femoral fracture) are needed. Odanacatib, a selective cathepsin K inhibitor, is a promising new approach to the inhibition of osteoclastic resorption, with the potential to uncouple bone formation from bone resorption. Results regarding its anti-fracture efficacy are expected in the coming months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Drugs available for the prevention and treatment of osteoporosis impact upon BMD and fracture risk, although their effect on muscle or fat mass is not well studied [100,101].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [101]
Experimental — accuracy not yet measuredIn the citing paper
“Drugs available for the prevention and treatment of osteoporosis impact upon BMD and fracture risk, although their effect on muscle or fat mass is not well studied [100,101].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
Self-citationConsensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis
(1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90218-e · Cited by 2,874
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Consensus Development Conference: A Cross-Cultural Study
Larsen, J. K., & Rogers, E. M. (1984) · Knowledge · doi:10.1177/107554708400500406 · Cited by 751
Kopera, H., & Ziegler, R. (1989) · Klinische Wochenschrift · doi:10.1007/bf01719785 · Cited by 749
Brown, J. P., Prince, R. L., Deal, C., Recker, R. R., Kiel, D. P., de Gregorio, L. H., Hadji, P., Hofbauer, L. C., Álvaro-Gracia, J. M., Wang, H., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0809010 · Cited by 610
Miller, P. D., Bolognese, M. A., Lewiecki, E. M., McClung, M. R., Ding, B., Austin, M., Liu, Y., & San Martin, J. (2008) · Bone · doi:10.1016/j.bone.2008.04.007 · Cited by 578
Research works printed but not linked: 1
- Papapoulos S, Bone HB, Dempster DW, Eisman J, Greenspan S, McClung M, Nakamura T, Shih J, Leung A, Santora A, Verbruggen N, Lombardi A. Phase 3 fracture trial of odanacatib for osteoporosis. Baseline characteristics and study design. Arthritis Rheum. 2013;65 Supp:S515–6.
Cited by
The effect of antiresorptive drugs on implant therapy: Systematic review and meta‐analysis
Stavropoulos, A., Bertl, K., Pietschmann, P., Pandis, N., Schiødt, M., & Klinge, B. (2018) · Clinical Oral Implants Research · doi:10.1111/clr.13282 · Cited by 137
Defining osteoblast and adipocyte lineages in the bone marrow
Pierce, J. L., Begun, D. L., Westendorf, J. J., & McGee‐Lawrence, M. E. (2018) · Bone · doi:10.1016/j.bone.2018.05.019 · Cited by 140
EMAS position statement: The ten point guide to the integral management of menopausal health
Neves-e-Castro, M., Birkhäuser, M., Samsioe, G., Lambrinoudaki, I. V., Palacios, S., Sánchez‐Borrego, R., Llaneza, P., Ceauşu, I., Depypere, H. T., Erel, C. T., et al. (2015) · Maturitas · doi:10.1016/j.maturitas.2015.02.003 · Cited by 110
Bauer, J. M., Cruz-Jentoft, A. J., Fielding, R. A., Kanis, J. A., Reginster, J.-Y., Bruyère, O., Cesari, M., Chapurlat, R., Al-Daghri, N., Dennison, E., et al. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00561-w · Cited by 83
Self-citationWang, Y., Zhang, H., Han, H., Zou, Y., Gao, Q.-L., & Yang, G. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.002 · Cited by 52
Metadata
- Authors
- Reginster, J. Y., Neuprez, A., Beaudart, C., Lecart, M. P., Sarlet, N., Bernard, D., Disteche, S., & Bruyere, O.
- Affiliations
- University of Liège (BE)
- Corresponding author
- Reginster, J. Y.
- Venue
- Drugs & Aging
- Published
- 2014-05-06
- Volume
- 31
- Issue
- 6
- Pages
- 413-424
- ISSN
- 1170-229X (ISSN-L)
- 1179-1969
- PMC
- PMC4033814
- OpenAlex
- W1972850638
- Cited by
- 29
- References
- 55
- Citations by year
- 2023: 1 · 2020: 4 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 3 · 2015: 7 · 2014: 1
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Drugs & Aging (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Teva Pharmaceutical Industries
- Danone
- Endocyte
- Servier
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- postmenopausal osteoporosis, antiresorptive agents, denosumab, odanacatib, cathepsin K inhibitors, RANKL inhibitor, bisphosphonates, selective estrogen receptor modulators, osteoporotic fractures, osteonecrosis of the jaw, atypical femoral fractures, bone resorption, fracture prevention
- MeSH terms
- Denosumab, Animals, Diphosphonates, Female, Humans, Osteoporosis, Postmenopausal, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Estrogen Receptor Modulators, Bone Density Conservation Agents, RANK Ligand, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis. https://app.cochat.ai/papers/10.1007/s40266-014-0179-z
- The paper
- Reginster, J. Y., Neuprez, A., Beaudart, C., Lecart, M. P., Sarlet, N., Bernard, D., Disteche, S., & Bruyere, O. (2014). Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis. Drugs & Aging. https://doi.org/10.1007/s40266-014-0179-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.